---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-23-000326"
form_type: "8-K"
ticker: "CDIO"
cik: "0001870144"
company_name: "Cardio Diagnostics Holdings, Inc."
filed_at: "2023-03-13T23:59:59+00:00"
generated_at: "2026-06-18T04:55:59.923210+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cardio Diagnostics enters $11.2M convertible debenture financing with Yorkville; receives initial $4.5M

## Summary
- Gross proceeds up to $11.2M from YA II PN, Ltd. (Yorkville); first tranche $5M debenture at 90% ($4.5M), second $6.2M upon SEC reg. effectiveness.
- Convertible at lower of $5.00 or 92% of avg two lowest daily VWAPs over 7 days, floor $0.55; 12-month maturity, 0% interest (15% on default).
- Proceeds to expand commercial adoption of PrecisionCHD and Epi+Gen CHD tests, launch new cardiovascular tests, and pursue payor coverage.
- Company has no deposits at Silicon Valley Bank; all deposits except <$250K in a major money center bank.

## SEC filing metadata
- accession: 0001079973-23-000326
- form_type: 8-K
- ticker: CDIO
- cik: 0001870144
- company_name: Cardio Diagnostics Holdings, Inc.
- filed_at: 2023-03-13T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870144/000107997323000326/0001079973-23-000326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870144/000107997323000326/cdio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-23-000326
- JSON: https://secwatch.observer/filing/0001079973-23-000326.json
- Plain text: https://secwatch.observer/filing/0001079973-23-000326.txt

## Key facts
- Debt Financings
  Cardio Diagnostics Holdings, Inc. incurred convertible notes of principal amount of $5 million with YA II PN, Ltd. (Yorkville) at 0.0% per annum maturing March 8, 2024.
  - Instrument: convertible notes
  - Principal: principal amount of $5 million
  - Counterparty: YA II PN, Ltd. (Yorkville)
  - Rate: 0.0% per annum
  - Maturity: March 8, 2024
  - Event: incurrence
  source text: the Company issued and sold to Yorkville a Convertible Debenture in the principal amount of $5 million for a purchase price of $4.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870144/000107997323000326/0001079973-23-000326-index.htm
- Material Agreements
  Cardio Diagnostics Holdings, Inc. entered into Securities Purchase Agreement with YA II PN, Ltd. (Yorkville) valued at up to $11.2 million (effective 2023-03-08).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: YA II PN, Ltd. (Yorkville)
  - Value: up to $11.2 million
  - Effective: 2023-03-08
  source text: On March 8, 2023, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with YA II PN, Ltd. (“Yorkville”), a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870144/000107997323000326/0001079973-23-000326-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.